CorMedix stock
CRMDNASDAQCorMedix Inc., HealthcareISIN US21900C3088
56Score 56 out of 100, Neutral
Price and trend
24 / 100
Price history
−58% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 36% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 18).
The price is 62% below its 52-week high. Largest decline in 17 years: 98% (April 2015 to May 2018).
Chart figures for advanced users
- SMA 50$7.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)18
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.84
- The lowest closing price of the last twelve months.
- Resistance$12.73
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CorMedix Inc. belongs to the Biotechnology industry (United States) and, with a market value of $377.25M, is number 267 of 289 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $336.4M (up 7.9%) and adjusted earnings per share of $0.49 (down 62.9%).
- MEQIRI Score 56 out of 100 (Neutral): rank 318 of 702 in Healthcare, median 53.
Show more
- The P/E is 5.9 (Biotechnology median 21.7, own median of recent years 5.2).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 487% of earnings over the last 12 months.Fundamentals 58
- High return on capitalReturn on invested capital 68.5% in fiscal 2025, Biotechnology median −24.3%.Profitability 80
- More cash than debtCash $355.15M, financial debt $145.42M.Stability 74
Weaknesses
- DilutionShare count up 152% since 2020.Capital allocation 50
- Share price fell sharplyDown 57% over the last 12 months.Momentum 12
- Volatile share priceVolatility 64% a year over the last 12 months.
Its standout strengths are valuation and profitability, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 59 to 56.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak momentum
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
UndervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 47.7% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 617% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating 48%, net 52%. Last 12 months: net 15%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 12 Nov 2026EPS reported −$0.19 (expected −$0.12)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 55.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.49−0.3%
- Revenue
- $336.4M−0.2%
- Earnings per share
- $0.03−55.9%
- Revenue
- $281.48M−2.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.2%Adjusted EBITDA guidance raised to $125 million to $140 million; revenue guidance of $325 million to $345 million reaffirmed.
“Turning to guidance, we are reaffirming our full-year 2026 revenue guidance with a range of $325 million to $345 million, and raising our full-year adjusted EBITDA guidance to a new range of $125 million to $140 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Dillione JanetSale
21 Jan 2026, Board
- Shares
- 10,000
- Price
- $6.88
- Value
- $68,800
- Dunton Alan WSale
30 Dec 2025, Board
- Shares
- 20,000
- Price
- $13.00
- Value
- $260,000
- Todisco JosephSale
18 Dec 2025, Chief Executive Officer
- Shares
- 30,000
- Price
- $12.00
- Value
- $360,000
Show 5 more
- Dillione JanetSale
9 Dec 2025, Board
- Shares
- 34,000
- Price
- $12.00
- Value
- $408,000
- Lefkowitz Steven WSale
9 Dec 2025, Board
- Shares
- 40,000
- Price
- $11.88
- Value
- $475,200
- Dillione JanetSale
2 Dec 2025, Board
- Shares
- 46,657
- Price
- $10.00
- Value
- $466,570
- Dillione JanetSale
24 Nov 2025, Board
- Shares
- 26,343
- Price
- $9.93
- Value
- $261,586
- Dillione JanetSale
14 Nov 2025, Board
- Shares
- 30,000
- Price
- $11.42
- Value
- $342,600
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CorMedix
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Lyell ImmunopharmaLYEL $384.52M33
- ARS PharmaceuticalsSPRY $383.01M33
- Fennec PharmaceuticalsFENC $382.23M56
- NeurogeneNGNE $377.68M32
- Contineum TherapeuticsCTNM $375.46M35
- Orchestra BioMed HoldingsOBIO $369.65M50
- YD BioYDES $368.32M36
- AlectorALEC $364.75M71
ETFs that hold CorMedix
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.47B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.02% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.